Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium

NCT01210222 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01210222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01210222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
June 6, 2011
Completion date
July 16, 2016
Enrollment
35 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, variant with squamous differentiation, endometrial serous adenocarcinoma, endometrioid stromal sarcoma, recurrent uterine corpus carcinoma